“Global Antifungal Drugs market set to grow to $17bn by 2024” says new Visiongain report

04 June 2019
Pharma

Visiongain has published a new pharma report Global Antifungal Drugs Market Forecast 2019-2029: Azoles, Echinocandins, Polyenes, Allylamines, Voriconazole, Posaconazole, Clotrimazole, Isavuconazole, Fluconazole, Caspofungin, Micagunfin, Amphotericin, Lamisil, Dermatophytosis, Aspergillosis, Candidiasis.

The global antifungal drugs market is estimated to have reached $14bn in 2018 and is expected to grow at a CAGR of 3.8% during the forecast period. In 2018, the global antifungal drugs market was dominated by Azoles.

This report profiled the selected companies: Abbott Laboratories, Bayer AG, Enzon Pharmaceuticals, Inc., Gilead Sciences, Inc., GlaxoSmithKline, Kramer Laboratories, Inc., Merck & Co., Inc., Novartis AG, Pfizer, Sanofi S.A. and others.

The lead analyst commented that "Market penetration and adoption of new technologies entering the market for antifungal drugs will be crucial for market growth.

The antifungal drugs market is mainly driven by the incidence and prevalence rate of antifungal infections. Moreover, cost-effective products, growing population of immunocompromised individuals and minimal side-effects are other factors that will drive market growth. However, antifungal drugs market has some restraints such as the presence of alternative therapies."

Notes for Editors
If you are interested in a more detailed overview of this report, please send an e-mail to sara.peerun@visiongain.com or call her on +44 (0) 207 336 6100.

About Visiongain
Visiongain is one of the fastest growing and most innovative independent media companies in Europe. Based in London, UK, Visiongain produces a host of business-to-business reports focusing on the automotive, aviation, chemicals, cyber, defence, energy, food & drink, materials, packaging, pharmaceutical and utilities sectors.

Visiongain publishes reports produced by analysts who are qualified experts in their field. Visiongain has firmly established itself as the first port of call for the business professional who needs independent, high-quality, original material to rely and depend on.

Recent News

“Global Vaccines Sales market set to grow to $75bn by 2024” says new Visiongain report

Progress in R&D in the therapeutic vaccine field will yield revolutionary results and answer unmet medical needs. This will also lead to more innovative approaches to vaccine development.

25 June 2019

Read

“Global Inflammatory Bowel Diseases (IBD) Drug Market is estimated to reach $8.6bn by 2024” says new Visiongain report

Revenue growth will be driven by rising incidence and prevalence owing to modern lifestyles and improved awareness and diagnosis.

21 June 2019

Read

“Top 25 Vaccines market set to grow to $41bn by 2024” says new Visiongain report

There is an increasing focus to identify diseases that currently do not have a vaccine.

20 June 2019

Read

“Global Ophthalmic Drugs market set to grow to $33bn by 2024” says new Visiongain report

The market for ophthalmic drugs is a growing one.

17 June 2019

Read

Kelloggs
3m
Thales
Shell
TEVA
Lockheed-Martin
Pfizer
Raytheon
Halliburton
Du-Pont
Honeywell
Daimler
BASF
Bayer
BP
BAE-Systems
Unilever